General Information of Drug Combination (ID: DC5JWCU)

Drug Combination Name
Vandetanib Vincristine
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Vandetanib   DMRICNP Vincristine   DMINOX3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DU-145
Zero Interaction Potency (ZIP) Score: 4.78
Bliss Independence Score: 13.7
Loewe Additivity Score: 4.39
LHighest Single Agent (HSA) Score: 14.55

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Vandetanib
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [2]
Vandetanib Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [5]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Inhibitor [5]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Vandetanib Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [7]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Vandetanib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Vandetanib Interacts with 22 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2) OTKOZRZP PLOD2_HUMAN Increases Expression [9]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Increases Expression [9]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [9]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) OTJKOMXE BNI3L_HUMAN Increases Expression [9]
Protein FAM13A (FAM13A) OTZ6GN0Q FA13A_HUMAN Increases Expression [9]
Phosphoglycerate kinase 1 (PGK1) OT6V1ICH PGK1_HUMAN Increases Expression [9]
Calbindin (CALB1) OTM7IXDG CALB1_HUMAN Increases Expression [9]
Prothymosin alpha (PTMA) OT2W4T1M PTMA_HUMAN Decreases Expression [9]
Trypsin-2 (PRSS2) OTOMVUWL TRY2_HUMAN Increases Expression [9]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Increases Expression [9]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3) OT2HZK5M GTR3_HUMAN Increases Expression [9]
Histone H1.2 (H1-2) OT0AVI4M H12_HUMAN Increases Expression [9]
DNA mismatch repair protein Msh3 (MSH3) OTD3YPVL MSH3_HUMAN Decreases Expression [9]
Pro-adrenomedullin (ADM) OT7T0TA4 ADML_HUMAN Increases Expression [9]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [10]
Collagen alpha-3(IV) chain (COL4A3) OT6SB8X5 CO4A3_HUMAN Increases Expression [9]
Solute carrier family 2, facilitated glucose transporter member 14 (SLC2A14) OTBFIOVY GTR14_HUMAN Increases Expression [9]
Protein NDRG1 (NDRG1) OTVO66BO NDRG1_HUMAN Increases Expression [9]
TSC22 domain family protein 3 (TSC22D3) OT03UM03 T22D3_HUMAN Increases Expression [9]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [11]
Hypoxia-inducible lipid droplet-associated protein (HILPDA) OTEID3ZM HLPDA_HUMAN Increases Expression [9]
Insulin-induced gene 2 protein (INSIG2) OTX4VY51 INSI2_HUMAN Increases Expression [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DOT(s)
Indication(s) of Vincristine
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [3]
Adult kidney Wilms tumor N.A. Approved [4]
Beckwith-Wiedemann syndrome N.A. Approved [4]
Burkitt lymphoma N.A. Approved [4]
Central nervous system neoplasm N.A. Approved [4]
Childhood acute lymphoblastic leukemia N.A. Approved [4]
Childhood kidney Wilms tumor N.A. Approved [4]
Hamartoma N.A. Approved [4]
Kidney neoplasm N.A. Approved [4]
Leukemia N.A. Approved [4]
MALT lymphoma N.A. Approved [4]
Nodal marginal zone lymphoma 2A85.0 Approved [4]
Plasma cell myeloma 2A83.1 Approved [4]
Primitive neuroectodermal tumor N.A. Approved [4]
Splenic marginal zone lymphoma N.A. Approved [4]
Testicular lymphoma N.A. Approved [4]
Wilms tumor N.A. Approved [4]
Classic Hodgkin lymphoma N.A. Investigative [4]
Follicular lymphoma 2A80 Investigative [4]
Neuroblastoma 2D11.2 Investigative [4]
Vincristine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [12]
------------------------------------------------------------------------------------
Vincristine Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [13]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [14]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [16]
------------------------------------------------------------------------------------
Vincristine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [17]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [17]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [18]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast adenocarcinoma DCQ6T3N MDA-MB-468 Investigative [19]
Adenocarcinoma DCPU3GE OVCAR3 Investigative [1]
Adult T acute lymphoblastic leukemia DCQLVFF MOLT-4 Investigative [1]
Lung adenocarcinoma DCEK1VY HOP-62 Investigative [1]
Lung adenocarcinoma DC5OBRW NCI-H522 Investigative [1]
Malignant melanoma DCZ8EAP LOX IMVI Investigative [1]
Mixed endometrioid and clear cell carcinoma DCP3NTB IGROV1 Investigative [1]
Renal cell carcinoma DC0WMT1 SN12C Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
4 Vincristine FDA Label
5 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
6 Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
7 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
8 FDA label of Vandetanib. The 2020 official website of the U.S. Food and Drug Administration.
9 ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer. 2006 Jan 15;118(2):483-9. doi: 10.1002/ijc.21340.
10 Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. Br J Cancer. 2013 Jul 9;109(1):164-71. doi: 10.1038/bjc.2013.306. Epub 2013 Jun 25.
11 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
14 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
15 L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
16 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
17 Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
18 Drug Interactions Flockhart Table
19 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165